二甲双胍抑制腹主动脉瘤进展:随机安慰剂对照临床试验
这项概念验证随机双盲安慰剂对照试验在58例非糖尿病肾下腹主动脉瘤患者中比较二甲双胍2 g与安慰剂,因COVID-19疫情未达到170例招募目标。基线至6、12、18个月的最大主动脉直径和动脉瘤体积变化在两组间均无显著差异。患者对二甲双胍依从性高且耐受性良好,但研究把握度不足,需更大规模更长随访的随机对照试验。
要点
- 二甲双胍2 g与安慰剂相比,腹主动脉瘤最大直径和体积变化无显著差异。
- 58例完成12个月治疗期患者的药物依从性为94.9%。
- 研究因COVID-19疫情未达到170例招募目标,把握度不足。
核心结论
- 二甲双胍组与安慰剂组的腹主动脉瘤增长无差异。
- 患者对二甲双胍治疗依从性极佳且耐受性良好。
- 鉴于研究把握度不足,需更大规模、更长随访的随机对照试验以检测更小的治疗效应。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验,比较二甲双胍2 g与安慰剂。
- 纳入58例非糖尿病肾下腹主动脉瘤患者,最大主动脉直径3.0 cm至4.9 cm,经14天导入期评估药物耐受性。
- 因COVID-19疫情未达到170例的招募目标。
- 在基线、治疗6个月和12个月后以及18个月随访时使用CT血管造影测量最大主动脉直径和动脉瘤体积。
- 预设主要结局为基线至12个月访视间最大主动脉直径变化。
主要发现
- 二甲双胍组与安慰剂组基线至6个月最大主动脉直径差异为-0.10 mm(95%CI -0.62至0.43 mm;p=0.71)。
- 基线至12个月最大主动脉直径差异为0.16 mm(95%CI -0.70至1.02 mm;p=0.72)。
- 基线至18个月最大主动脉直径差异为0.31 mm(95%CI -0.86至1.48 mm;p=0.59)。
- 基线至6、12、18个月主动脉体积差异分别为-0.19 cm3(95%CI -2.52至2.14 cm3;p=0.87)、1.65 cm3(95%CI -2.45至5.76 cm3;p=0.42)和2.10 cm3(95%CI -3.45至7.65 cm3;p=0.45)。
- 58例完成12个月治疗期的随机患者中,药物依从性为94.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究因COVID-19疫情未达到170例的招募目标。
- 研究把握度不足。
- 需更大规模、更长随访的随机对照试验以检测更小的治疗效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Preliminary observational studies have associated metformin prescription for diabetes treatment with reduced abdominal aortic aneurysm (AAA) growth progression. This proof of concept randomised controlled trial aimed to evaluate the efficacy of metformin intake on AAA growth progression in patients without diabetes. METHODS: This was a randomised, double blind, placebo controlled clinical trial of 2 g metformin vs. placebo in non-diabetic patients with AAA. Fifty eight patients with an infrarenal AAA with a maximum aortic diameter between 3.0 cm and 4.9 cm were included after a 14 day run in phase assessing drug tolerability. The recruitment target of 170 patients was not achieved due to the COVID-19 pandemic. The maximum aortic diameter and aneurysm volume were measured at baseline, after six and 12 months of treatment, and at 18 months follow up using computed tomography angiography. The pre-specified primary outcome was maximum aortic diameter change between baseline and 12 month visit. RESULTS: Differences in maximum aortic diameter from baseline to six, 12, and 18 months between the metformin and placebo groups were -0.10 mm (95% confidence interval [CI] -0.62 - 0.43 mm; p = .71), 0.16 mm (95% CI -0.70 - 1.02 mm; p = .72), and 0.31 mm (95% CI -0.86 - 1.48 mm; p = .59), respectively. The corresponding differences in aortic volume were -0.19 cm3 (95% CI -2.52 - 2.14 cm3; p = .87), 1.65 cm3 (95% CI -2.45 - 5.76 cm3; p = .42), and 2.10 cm3 (95% CI -3.45 - 7.65 cm3; p = .45). Amongst 58 randomised patients who completed the 12 month treatment phase, medication adherence was 94.9%. CONCLUSION: No difference in AAA growth between the metformin and placebo groups was observed. Patients had excellent adherence and tolerability to metformin therapy. Considering the lack of power of the study, larger randomised controlled trials with longer follow up are required to detect smaller treatment effects.
引用
- Eilenberg W, Klopf J, Sotir A, et al. Editor's Choice - Metformin to Inhibit Progression of Abdominal Aortic Aneurysm: A Randomised, Placebo Controlled Clinical Trial. Eur J Vasc Endovasc Surg. 2025. PMID: 40311839. doi:10.1016/j.ejvs.2025.04.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。